Efficacy of EDP ± mitotane chemotherapy in the treatment of metastatic adrenocortical carcinoma. Predictive and prognostic factors of efficacy

Introduction. Adrenocortical carcinoma (ACC) is an orphan disease with an unfavorable prognosis. The most effective therapeutic option in the treatment of ACC is EDP plus mitotane combination chemotherapy. However, no studies comparing the efficacy of the EDP regimen with or without mitotane have been published.

Materials and methods. A retrospective analysis of health records of patients with histologically confirmed metastatic ACC, who received at least one chemotherapy cycle with EDP ± mitotane. The study included 73 patients, 49 of which received a combination of EDP and mitotane and 24 were treated with EDP chemotherapy.

Results. The objective response rate was 18,4 % in the EDP + mitotane group versus 4,1 % in the EDP group. Disease control was reported in 25 (51 %) and 13 (54,2 %) patients, respectively. No significant differences were found in progression-free survival (PFS) rates between the EDP and EDP + mitotane groups; the median PFS rate was 6,5 and 6,0 months, respectively. The median overall survival (OS) in the total population was 20,9 months; no significant differences were found between the groups. However, an increase in median PFS was observed in patients who achieved a therapeutic concentration of mitotane. Moreover, the achievement of therapeutic mitotane concentrations was the only factor significantly associated with improved PFS (HR 0.44, p = 0.006). Significant unfavorable prognostic factors associated with lower OS were Ki-67 level in the primary tumor > 20 % (HR 10.5, p = 0.006) and more than 1 site of metastases (HR 3.82, p = 0.02).

Conclusions. This study showed that the addition of mitotane to EDP chemotherapy does not improve the median PFS and OS in the total patient population, however, the achievement of therapeutic mitotane concentrations is significantly associated with improved progression-free survival.

1. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49 (11):2579–2586. PMID: 23 561 851. DOI: 10.1016/j.ejca.2013.02.034

2. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 2011;96 (6):1844–1851. PMID: 21 470 991. DOI: 10.1210/jc.2010–2676

3. Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007; 356 (23):2372–2380. PMID: 17 554 118. DOI: 10.1056/NEJMoa063360

4. Megerle F, Herrmann W, Schloetelburg W, et al. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2018;103 (4):1686–1695. PMID: 29 452 402. DOI: 10.1210/jc.2017–02591.

5. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of DDD, DDA, and DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 2011;96 (6):1844–1851. PMID: 21 470 991. DOI: 10.1210/jc.2010–2676.

6. ZGonzalez RJ, Tamm EP, Ng C, et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007;142 (6):867–875; discussion 867–875. PMID: 18 063 070. DOI: 10.1016/j.surg.2007.09.006.

7. Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169 (3):263–270. PMID: 23 704 714. DOI: 10.1530/EJE-13–0242.

8. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366 (23):2189–2197. PMID: 22 551 107. DOI: 10.1056/NEJMoa1200966.

9. Berutti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005 Sep;12 (3):657–66. PMID: 16 172 198. DOI: 10.1677/erc.1.01025.

10. Laganа M, Grisanti S, Cosentini D, et al. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. Cancers (Basel). 2020;12 (4). PMID: 32 290 298. DOI: 10.3390/cancers12040941.

11. Beuschlein F, Weigel J, Saeger W, et al. Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. J Clin Endocrinol Metab. 2015; 100 (3): 841–849. PMID: 25 559 399. DOI: 10.1210/jc.2014–3182.

12. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMOEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2020; 31 (11):1476– 1490. DOI: 10.1016/j.annonc.2020.08.2099

13. Kerkhofs TM, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98 (12):4759–4767. PMID: 24 057 287. DOI: 10.1210/jc.2013–2281.